

## 6. Literaturverzeichnis

- Anfosso F, Bardin N, Frances V, Vivier E, Camoin-Jau L, Sampol J, Dignat-George F. Activation of human endothelial cells via S-endo-1 antigen (CD146) stimulates the tyrosine phosphorylation of focal adhesion kinase p125(FAK). *J Biol Chem.* 1998 Oct 9;273(41):26852-6.
- Anfosso F, Bardin N, Vivier E, Sabatier F, Sampol J, Dignat-George F. Outside-in Signaling Pathway Linked to CD146 Engagement in Human Endothelial Cells. *The Journal of Biological Chemistry* 2001; 276/2: 1564-1569.
- Auer RL, Bertoni F, Jones C, COTTER FE. The class II tumor suppressor gene RARRES3 maps to 11q12, not 11q23. *Leukemia* 2002; 16: 1396-1397.
- Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biologie of ovarian cancer. *Semin. Oncol.* 1998; 25: 281-304.
- Aunoble B, Sanches R, Didier E, Bignon YJ. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review). *Int. J. Oncol.* 2000;16: 567-576.
- Baker KM, Wei G, Schaffner AE, Ostrowski MC. Ets-2 and components of mammalian SWI/SNF form a repressor complex that negatively regulates the BRCA1 promoter. *J Biol Chem.* 2003 May 16;278(20):17876-84.
- Bast RC Jr, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A. Cell growth regulation in epithelial ovarian cancer. *Cancer* 1993; 71: 1597-1601.
- Bast RC Jr, Jacobs I, Berchuck A. Malignant transformation of ovarian epithelium. *J Natl Cancer Inst.* 1992 Apr 15;84(8):556-8.
- Belletti B, Drakas R, Morrione A, Tu X, Prisco M, Yuan T, Casaburi I, Baserga R. Regulation of Id1 protein expression in mouse embryo fibroblasts by the type 1 insulin-like growth factor receptor. *Exp Cell Res.* 2002 Jul 1;277(1):107-18.

- Berchuck A, Kamel A, Whitaker RR, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. *Cancer Research* 1990; 50: 4087-4091.
- Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC Jr. Growth regulation and transformation of ovarian epithelium. *Cancer*. 1993 Jan 15;71(2 Suppl): 545-51.
- Berchuck A. Biomarkers in the Ovary. *J. Cell Biochem*. 1995; 23S: 223-226.
- Bist A, Fielding CJ, Fielding PE. p53 regulates caveolin gene transcription, cell cholesterol, and growth by a novel mechanism. *Biochemistry* 2000; 39:1966-1972.
- Bos JL. ras oncogenes in human cancer: a review. *Cancer Res*. 1989 Sep 1;49(17):4682-9.
- Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. *Oncogene* 1998; 17: 1395-1413.
- Cano E, Hazzalin CA, Kardalidou E, Buckle RS, Mahadevan LC. Neither ERK nor JNK/SAPK MAP kinase subtypes are essential for histone H3/HMG-14 phosphorylation or c-fos and c-jun induction. *J Cell Sci*. 1995 Nov;108 ( Pt 11):3599-609.
- Casanova B, de la Fuente MT, Garcia-Gila M, Sanz L, Silva A, Garcia-Marco JA, Garcia-Pardo. The class II tumor-suppressor gene RARRES3 is expressed in B cell lymphocytic leukemias and down-regulated with disease progression. *Leukemia* 2001; 15: 1521-1526.
- Chelbi-Alix MK, Pelicano L. Retinoic acid and interferon signaling cross talk in normal and RA-resistant APL cells. *Leukemia*. 1999 Aug;13(8):1167-74.
- Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Anal Biochem*. 1987 Apr;162(1):156-9.

- Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. *Cell*. 1994 Jun 17;77(6):841-52.
- Crews CM, Alessandrini A, Erikson RL. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. *Science*. 1992 Oct 16;258(5081):478-80.
- Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. *Science* 1994; 265:1582-1584.
- Davis M, Hitchcock A, Foulkes WD, Campbell IG. Retinment of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. *Cancer Research* 1996; 56: 741-744.
- DeClue JE, Papageorge AG, Fletcher JA, Diehl SR, Ratner N, Vass WC, Lowy DR. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. *Cell*. 1992 Apr 17;69(2):265-73.
- Deucher A, Nagpal S, Chandraratna RAS, DiSepio D, Robinson NA, Dashti SR, Echert RL. The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. *International Journal of Oncology* 2000; 17: 1195-1203.
- Dhanasekaran N, Tsim ST, Dermott JM, Onesime D. Regulation of cell proliferation by G proteins. *Oncogene*. 1998 Sep 17;17(11 Reviews):1383-94.
- Dietrich, K (Hrsg.) *Gynäkologie und Geburtshilfe*; Springer Verlag 2000; 604-610.
- DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RAS, Nagpal S. Identification and characterisation of a retinoid-induced class II tumor suppressor/growth regulatory gene. *Proc. Natl. Acad. Sci*. 1998; 95: 14811-14815.
- Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. *Proc. Natl. Acad. Sci. USA* 1995; 92/17: 7686-7689.

- Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, DiMao D, Hazarika P, Jakson B, Breuer-McHam J, Young J, Clayman G, Lippman SM, Chandraratna RAS, Robinson NA, Deucher A, Eckert RL, Nagpal S. Expression of a Retinoid-inducible Tumor-Suppressor, *Tazarotene-inducible Gene-3*, Is Decreased in Psoriasis and Skin Cancer. *Clinical Cancer Research* 2000; 6: 3249-3259.
- Easton DF, Bishop DT, Ford D, Crockford GP. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium. *Am. J. Hum. Genet.* 1993; 52: 678-701.
- Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. The Breast Cancer Linkage Consortium. *Am. J. Hum. Genet.* 1995; 59: 265-271.
- Erhardt P, Schremser EJ, Cooper GM. B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. *Mol Cell Biol.* 1999 Aug;19(8):5308-15.
- Evans TR, Kaye SB. Retinoids: present role and future potential. *Br J Cancer.* 1999 Apr; 80(1-2):1-8.
- Foulkes WD, Campbell IG, Stamp GW, Trowsdale J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. *British Journal of Cancer* 1993; 67/2 268-273.
- Futreal PA, Liu Q, Shattuck-Eidens D, Cochran C, Harshman K, Tavtigian S, Bennett LM, Haugen-Strano A, Swensen J, Miki Y, et al. BRCA1 mutations in primary breast and ovarian carcinomas. *Science* 1994; 266:120-122.
- Gabra H, Taylor L, Cohen BB, Lessels A, Eccles DM, Leonard RCT, Smyth JF. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. *Br. J. Cancer* 1995; 72: 367-375.

- Gabra H, Watson JE, Taylor KJ, Mackay J, Leonard RCT, Steel CM, Porteous DJ, Smyth JF. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. *Cancer Research* 1996; 56/5: 950-954.
- Galbiati F, Volonte D, Engelman JA, Watanabe G, Burk R, Pestell RG, Lisanti MP. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. *EMBO J.* 1998 Nov 16;17(22):6633-48.
- Galetic I, Maira SM, Andjelkovic M, Hemmings BA. Negative regulation of ERK and Elk by protein kinase B modulates c-Fos transcription. *J Biol Chem.* 2003 Feb 14;278(7):4416-23.
- Hajnal A, Klemenz R, Schäfer R. Substraction cloning of *H-rev 107*, a gene specifically in *H-ras* resistant fibroblasts. *Oncogene* 1994; 9: 479-490.
- Harten H-U, Nägerl H, Schulte H-D. *Statistik für Mediziner*; VHC Verlagsgesellschaft mbH 1993; 126
- Hartge P, Whittmore AS, Itnyre J, Mc Gowan L, Cramer D. Rates and risks of ovarian cancer in subgroups of white woman in the United States. The Collaborative Ovarian Cancer Group. *Obstet. Gynecol.* 1994; 84: 760-764.
- Hauptmann S, Denkert C, Koch I, Petersen S, Schlüns K, Reles A, Dietel M, Petersen I. Genetic Alteration in Epithelial Ovarian Tumors Analyzed by Comparative Genomic Hybridization. *Human Pathology* 2002; 33/6: 632-641.
- Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarr JR, Linehan WM, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. *Proc Natl Acad Sci U S A.* 1994 Oct 11;91(21):9700-4.
- Honda H, Oda H, Nakamoto T, Honda Z, Sakai R, Suzuki T, Saito T, Nakamura K, Nakao K, Ishikawa T, Katsuki M, Yazaki Y, Hirai H. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. *Nat Genet.* 1998 Aug;19(4):361-5.

- Horn LC, Fricke K, Krugmann J. Histologische Klassifikation und morphologische Prognosefaktoren bei malignen Ovarialtumoren. Zentralblatt für Gynäkologie 1995; 117: 335-345.
- Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ. Coordinately up-regulated genes in ovarian cancer. Cancer Res. 2001 May 15;61(10):3869-76.
- Huang S-L, Shyu R-Y, Yeh M-Y, Jiang S-Y. Cloning and characterization of a novel retinoid-inducible gene 1 (*RIG1*) deriving from human gastric cancer cells. Molecular and Cellular Endocrinology 2000; 159: 15-24.
- Huang S-L, Shyu R-Y, Yeh M-Y, Jiang S-Y. The Retinoid-inducible Gene I: Effect on Apoptosis and Mitogen activated Kinase Signal Pathways. Anticancer Research 2002; 22: 799-804.
- Hunter T. Oncoprotein networks. Cell 1997; 88: 333-346.
- Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schäfer R. Transcriptional and translational downregulation of *H-REV 107*, a class II tumor suppressor gene located on human chromosome 11q11-12. Oncogene 1998; 17: 1305-1312.
- Johnson JP, Rothbacher U, Sers C. The progression associated antigen MUC18: a unique member of the immunoglobulin supergene family. Melanoma Research 1993; 3: 337-340.
- Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, Arisio R, Giardina G, Sismondi P. Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Research 1995; 15: 1501-1510.
- Khosravi-Far R, Der CJ. The Ras signal transduction pathway. Cancer Metastasis Rev. 1994 Mar;13(1):67-89.
- Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol. 1995 Nov;15(11):6443-53.

- Kolch W, Heidecker G, Lloyd P, Rapp UR. Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. *Nature*. 1991 Jan 31;349(6308):426-8.
- Kuske MDA, Johnson JP. Assignment of the human melanoma cell adhesion molecule gene (MCAM) to chromosome 11 band q23.3 by radiation hybrid mapping. *Cytogenetics and Cell Genetics* 1999; 87: 285.
- Launonen V, Mannermaa A, Stenbäck F, Kosma VM, Puistola U, Huusko P, Anttila M, Bloigu R, Saarikoski S, Kauppila A, Winqvist R. Loss of heterozygosity at chromosome 3, 6, 8, 11, 16 and 17 in ovarian cancer: correlation to clinicopathological variables. *Cancer Genetics and Cytogenetics* 2000; 122: 49-54.
- Launonen V, Stenbäck F, Puistola U, Bloigu R, Huusko P, Kytölä S, Kauppila A, Winqvist R. Chromosome 11q22.3-q25 LOH in Ovarian Cancer: Association with a More Aggressive Disease Course and Involved Subregions. *Gynecologic Oncology* 1998; 71: 299-304.
- Lehmann ML, Holzmann B, Breitbart EW, Schmiegelow P, Riethmüller G, Johnson JP. Discrimination between Benign and Malignant Cells of Melanocytic Lineage by Two Novel Antigens, a Glycoprotein with a Molecular Weight of 113,000 and a Protein with a Molecular Weight of 76,000. *Cancer Research* 1987; 47: 841-845.
- Lehmann ML, Riethmüller G, Johnson JP. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. *Proc. Natl. Acad. Sci. USA* 1989; 86: 9891-9895.
- Lotz K, Kellner T, Heitmann M, Nazarenko I, Noske A, Malek A, Gontarewicz A, Schäfer R, Sers C. Suppression of the TIG3 tumor suppressor gene in human ovarian carcinomas is mediated via mitogen-activated kinase-dependent and -independent mechanisms. *Int J Cancer*. 2005 Oct 10;116(6):894-902.
- Luca M, Hunt B, Bucana CD, Johnson JP, Fidler IJ, Bar-Eli M. Direct correlation between MUC18 expression and metastatic potential of human melanoma cells. *Melanoma Research* 1993; 3: 35-41.

- Lynch HT, Casey JM, Lynch J, Wihte TEK, Godwin AK. Genetics and Ovarian Carcinoma. *Seminars of Oncology* 1998; 25/3: 265-280.
- Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. *Cell*. 1993 Apr 23;73(2):381-93.
- Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, Baylin SB, Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. *Nat Med*. 1995 Jul;1(7):686-92.
- Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994; 266: 66-71.
- Nagata Y, Todokoro K. Requirement of activation of JNK and p38 for environmental stress-induced erythroid differentiation and apoptosis and of inhibition of ERK for apoptosis. *Blood*. 1999 Aug 1;94(3):853-63.
- Nakamura I, Jimi E, Duong LT, Sasaki T, Takahashi N, Rodan GA, Suda T. Tyrosine Phosphorylation of p130<sup>CAS</sup> Is Involved in Actin Organization in Osteoclasts. *The Journal of Biological Chemistry* 1998; 273/18: 11144-11149.
- O'Briant K, Chrysson N, Hunter V, Tyson F, Tanner M, Daly L, George SL, Berchuck A, Soper J, Fowler W, et al. Ha-ras polymorphisms in epithelial ovarian cancer. *Gynecol Oncol*. 1992 Jun;45(3):299-302.
- Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC, Ostrowski MC. Activation of ras-Mitogen-activated Protein Kinase Pathway and Phosphorylation of ets-2 at Position Threonine 72 in Human Ovarian Cancer Cell Lines. *Cancer Research* 1998; 58: 2253-2259.
- Petch LA, Bockholt SM, Bouton A, Parson JT, Burrige K. Adhesion-induced tyrosine phosphorylation of the p130 SRC substrate. *Journal of Cell Science* 1995; 108: 1371-1379.



- Qiu RG, Chen J, Kim D, McCormick F, Symons M. An essential role for Rac in Ras transformation. *Nature*. 1995 Mar 30;374(6521):457-9. b
- Qiu RG, Chen J, McCormick F, Symons M. A role for Rho in Ras transformation. *Proc Natl Acad Sci U S A*. 1995 Dec 5;92(25):11781-5. a
- Riede, Schäfer Allgemeine und spezielle Pathologie; 3. Auflage; Georg Thieme Verlag 1993
- Rohwedel J, Guan K, Wobus AM. Induction of cellular differentiation by retinoic acid in vitro. *Cells Tissues Organs*. 1999;165(3-4):190-202.
- Sager R. Expression genetics in cancer: Shifting the focus from DNA to RNA. *Proc. Natl. Acad. Sci. USA* 1997; 94: 952-955.
- Satoh T, Kaziro Y. Ras in signal transduction. *Semin Cancer Biol*. 1992 Aug;3(4):169-77.
- Schaap D, van der Wal J, Howe LR, Marshall CJ, van Blitterswijk WJ. A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. *J Biol Chem*. 1993 Sep 25;268(27):20232-6.
- Schultz DC, Vanderveer L, Berman DB, Hamilton TC, Wong AJ, Godwin AK. Identification of two candidate tumor suppressor genes on chromosome 17p13.3. *Cancer Research* 1996; 56: 1997-2002.
- Schulze A, Lehmann K, Jefferies HB, McMahon M, Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. *Genes Dev*. 2001 Apr 15;15(8):981-94.
- Sers C, Emmenegger U, Husmann K, Bucher K, Andres A-C, Schäfer R. Growth-inhibitory Activity and Downregulation of the Class II Tumor-suppressor Gene *H-rev 107* in Tumor Cell Lines and Experimental Tumors. *The Journal of Cell Biology* 1997; 136/4: 935-944.
- Sers C, Riethmüller G, Johnson JP. *MUC18*, a Melanoma-Progression Associated Molecule, and Its Potential Role in Tumor Vascularization and Hematogenous Spread. *Cancer Research* 1994; 54: 5689-5694.

- Sers C, Husmann K, Nazarenko I, Reich S, Wiechen K, Zhumabayeva B, Adhikari P, Schröder K, Gontarewicz A, Schäfer R. The class II tumor suppressor gene *H-REV 107-1* is a target of interferon-regulatory factor-1 and is involved in IFN $\gamma$ -induced cell death in human ovarian carcinoma cells. *Ocogene* 2002; 21: 2829-2839. b
- Sers C, Tchernitsa OI, Zuber J, Diatchenko L, Zhumabayeva B, Desai S, Htun S, Hyder K, Wiechen K, Agoulnik A, Scharff KM, Siebert PD, Schäfer R. Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arrays. *Advan. Enzyme Regul.* 2002; 42: 63-82. a
- Sers C., Kirsch K, Rothbacher U, Riethmüller G, Johnson JP. Genomic organization of the melanoma-associated glycoprotein MUC18: Implication for the evolution of the immunoglobulin domains. *Proc. Natl. Acad. Sci. USA* 1993; 90: 8514-8518.
- Shih I-M, Elder DE, Hsu MY, Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. *Am. J. Pathol.* 1994;145: 837-45.
- Shih I-M, Hsu M-Y, Palazzo JP, Herlyn M. The Cell-Cell Adhesion Receptor Mel-CAM Acts as a Tumor Suppressor in Breast Carcinoma. *American Journal of Pathology* 1997; 151/3: 745-751.
- Shih I-M, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal antibody, MN-4, on paraffin-embedded tissue. *Mod Pathol.* 1998; 11: 1098-1106.
- Shih I-M. The role of CD146 (Mel-CAM) in biology and pathology. *Journal of Pathology* 1999; 189: 4-11.
- Shyu R-Y, Jiang S-Y, Chou J-M, Shih Y-L, Lee M-S, Yu L-C, Chao P-C, Hsu Y-J, Jao S-W. RARRES3 expression positively correlated to tumor differentiation in tissues of colorectal adenocarcinoma. *British Journal of Cancer* 2003; 89: 146-151.

- Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. *Cancer Cell*. 2003 Jun;3(6):525-30.
- Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. *Science* 1989; 244: 707-712.
- Tanaka N, Taniguchi T. The interferon regulatory factors and oncogenesis. *Semin Cancer Biol*. 2000 Apr;10(2):73-81.
- Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. *Nat. Genet*. 1995; 9: 444-450.
- Tsao SW, Mok SC, Fey EG, Fletcher JA, Wan TS, Chew EC, Muto MG, Knapp RC, Berkowitz RS. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). *Exp Cell Res*. 1995; 218(2): 499-507.
- Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *Journal of Biological Chemistry* 1994; 269/7: 5241-5248.
- Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives – findings in a large cohort study. *Br. J. Cancer* 1995; 71: 1340-1342.
- Von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. Ras activation in human breast cancer. *Breast Cancer Research and Treatment* 2000; 62: 51-62.
- Westwick JK, Cox AD, Der CJ, Cobb MH, Hibi M, Karin M, Brenner DA. Oncogenic Ras activates c-Jun via a separate pathway from the activation of extracellular signal-regulated kinases. *Proc Natl Acad Sci U S A*. 1994 Jun 21;91(13):6030-4.
- Wiechen K, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, Zhumabayeva B, Siebert PD, Dietel M, Schafer R, Sers C. Caveolin-1 is down-regulated in human ovarian

- carcinoma and acts as a candidate tumor suppressor gene. *Am J Pathol.* 2001 Nov; 159(5):1635-43. a
- Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Schneider U. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. *Am J Pathol.* 2001 Mar;158(3):833-9. b
- Windbichler GH, Hausmaninger H, Stummvoll W, Graf AH, Kainz C, Lahodny J, Denison U, Muller-Holzner E, Marth C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. *Br J Cancer.* 2000 Mar;82(6):1138-44.
- Xie S, Luca M, Huang S, Gutman M, Reich R, Johnson JP, Bar-Eli M. Expression of MCAM/MUC18 by human melanoma cells leads to increased tumor growth and metastasis. *Cancer Research* 1997; 57: 2295-2303.
- Zhang D, Holmes WF, Wu S, Soprano DR, Soprano KJ. Retinoids and Ovarian Cancer. *Journal of Cellular Physiology* 2000; 185: 1-20.
- Zhumabayeva B, Diachenko L, Chenchik A, Siebert PD. Use of SMART™-Generated cDNA for gene expression studies in multiple human tumors. *BioTechniques* 2001; 30: 158-163.
- Zou Z, Gao C, Nagaich AK, Connell T, Saito S, Moul JW, Seth P, Appella E, Srivastava S. p53 regulates the expression of the tumor suppressor gene maspin. *J. Biol. Chem.* 2000; 275: 6051-6054.
- Zuber J, Tchernitsa OI, Hinzmann B, Schmitz A-C, Grips M, Hellriegel M, Sers C, Rosenthal A, Schäfer R. A genome-wide survey of RAS transformation targets. *Nature Genetics* 2000; 24: 144-152.